← Human Trials & Peer-Reviewed Studies

Differential effects of nicotine on alcohol consumption in men and women.

Plain-language guide to PMID 16565827 (2006): double-blind controlled clinical trial of Therapeutic nicotine (patch, non-peptide) in 22 men.

Key Facts

PMID
16565827
Journal
Psychopharmacology
Year
2006
Study type
Controlled Clinical Trial
Authors
Acheson A et al. (4 authors)
DOI
10.1007/s00213-006-0338-y

What This Study Did, in Plain Language

What Was Tested

This controlled clinical trial looks at Therapeutic nicotine (patch, non-peptide).

This experiment was designed to investigate the effects of nicotine on consumption and subjective and physiological effects of alcohol in healthy male and female social drinkers.

Why It Was Studied

Furthermore, because men and women differ in their responses to both drugs, it is possible that men and women also differ in their responses to the combination of nicotine and alcohol.

Who Took Part

According to the abstract, 22 men were involved.

The age groups tagged for this paper are adults, both men and women.

Healthy light smoking, social drinkers (22 men and 12 women) participated in a three-session, double-blind within-subject study.

Outcome measures included the number of alcoholic beverages consumed and subjective and physiological effects.

How the Study Was Run

The design is described as double-blind and placebo-controlled.

Neither the men nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.

What Was Measured

Topics PubMed links to this paper include Affect, Alcohol Drinking, Drug Interactions, Ethanol, Nicotine and Sex Factors.

What This Means in Plain Language

The paper is a double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 22 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2006 (Psychopharmacology), a journal based in Germany.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.